The Journal of urology
-
The Journal of urology · Jan 2001
Comparative StudyMedical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study.
We provide a relative cost comparison of medical versus surgical androgen suppressive therapy for prostate cancer. ⋯ Except for patients with short anticipated survivals current medical androgen suppressive treatment options are more costly than bilateral orchiectomy. There is a need for a cost comparable medical option to orchiectomy.
-
The Journal of urology · Jan 2001
Clinical TrialThe use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
Hormone refractory prostate cancer is dominated by osseous metastases leading to bone pain and pathological fractures. We assessed the clinical efficacy of bisphosphonate in the management of symptomatic skeletal metastases due to prostate cancer. ⋯ Bisphosphonate treatment of painful osseous metastases due to hormone refractory prostate cancer results in a significant pain decrease and a significant decrease in the daily consumption of analgesics in 75% of patients. Each characteristic is paralleled by an increase in the Karnofsky index, mainly due to better mobility. Bisphosphonate should have a definite role in the palliative management of symptomatic hormone refractory prostate cancer.
-
The Journal of urology · Nov 2000
ReviewNeoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?
Neoadjuvant hormonal ablation therapy has been used to decrease the rate of positive surgical margins in patients treated with radical prostatectomy. We reviewed the available literature to determine whether this therapy is indicated and beneficial. ⋯ Analysis of the available literature revealed no significant improvement in outcome to support the routine administration of neoadjuvant hormonal therapy before prostatectomy.
-
The Journal of urology · Nov 2000
Multicenter StudyLong-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia.
We assess clinical and urodynamic results of sacral nerve stimulation for patients with neurogenic (spinal cord diseases) urge incontinence and detrusor hyperreflexia resistant to parasympatholytic drugs. ⋯ Sacral nerve stimulation can be used as a reversible treatment option for refractory urge incontinence related to detrusor hyperreflexia in select patients with spinal lesions.